{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 470612083
| type              = mab
| image             = Tralokinumab 5L6Y.png
| alt               = 
| caption           = Tralokinumab [[fragment antigen-binding|Fab fragment]] bound to IL-13. From [[Protein Data Bank|PDB]] {{PDB2|5L6Y}}.
| mab_type          = mab
| source            = u
| target            = [[interleukin 13|IL-13]]
| tradename         =  
| Drugs.com         =
| MedlinePlus       =
| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US      = <!-- A / B            / C / D / X -->
| pregnancy_category=  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status      = 
| routes_of_administration = 
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| elimination_half-life = 
| excretion         = 
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number        = 1044515-88-9

| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = GK1LYB375A


| ATC_prefix        = none
| ATC_suffix        = 
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| PubChem           = 
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank          =
| KEGG = D09979
| C=6374 | H=9822 | N=1698 | O=2014 | S=44
| molecular_weight = 143.87 kg/mol
}}

'''Tralokinumab''' is a human monoclonal antibody which targets the cytokine [[interleukin 13]],<ref>{{cite journal |doi=10.1038/nrd2805 |title=Averting inflammation by targeting the cytokine environment |year=2010 |last1=Kopf |first1=Manfred |last2=Bachmann |first2=Martin F. |last3=Marsland |first3=Benjamin J. |journal=Nature Reviews Drug Discovery |volume=9 |issue=9 |pages=703–18 |pmid=20811382}}</ref> and is designed for the treatment of [[asthma]] and other inflammatory diseases.<ref>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Tralokinumab|publisher=[[American Medical Association]]|url=http://www.ama-assn.org/resources/doc/usan/tralokinumab.pdf}}</ref> Tralokinumab was discovered by [[Cambridge Antibody Technology]] scientists, using Ribosome Display, as CAT-354<ref name="peds.oxfordjournals.org">{{cite journal |doi = 10.1073/pnas.0602341103|title = Probing a protein–protein interaction by in vitro evolution|journal = Proc. Natl. Acad. Sci. USA|url = http://www.pnas.org/content/103/20/7619|last = Thom|first = G|last2 = Cockroft|first2 = AC|last3 = Buchanan|first3 = AG|last4 = Candotti|first4 = CJ|last5 = Cohen|first5 = ES|last6 = Lowne|first6 = D|last7 = Monk|first7 = |trans-title = P|last8 = Shorrock-Hart|first8 = CP|last9 = Jermutus|first9 = L|last10 = Minter|first10 = RR|displayauthors =|volume=103|pages=7619–7624|pmid=16684878|pmc=1458619}}</ref> and taken through pre-clinical and early clinical development.<ref>{{cite journal |doi=10.1111/j.1476-5381.2011.01659.x |title=Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma |year=2012 |last1=May |first1=RD |last2=Monk |first2=PD |last3=Cohen |first3=ES |last4=Manuel |first4=D |last5=Dempsey |first5=F |last6=Davis |first6=NHE |last7=Dodd |first7=AJ |last8=Corkill |first8=DJ |last9=Woods |first9=J |last10=Joberty-Candotti |first10=C |last11=Conroy |first11=LA |last12=Koentgen |first12=F |last13=Martin |first13=EC |last14=Wilson |first14=R |last15=Brennan |first15=N |last16=Powell |first16=J |last17=Anderson |first17=IK |journal=British Journal of Pharmacology |volume=166 |pages=177–193 |pmid=21895629 |issue=1|display-authors=8 |pmc=3415647 }}</ref> After 2007 it has been developed by [[MedImmune]], a member of the AstraZeneca group, where it is currently in Ph3 testing for asthma and Ph2b testing for atopic dermatitis.<ref>{{cite web|title=Pipeline|url=http://www.medimmune.com/research/pipeline|work=MedImmune|accessdate=11 June 2013}}</ref><ref>{{cite web|title=Studies found for CAT-354|url=http://www.clinicaltrials.gov/ct2/results?term=CAT-354|work=ClinicalTrials.gov|accessdate=11 June 2013}}</ref> This makes it one of the few fully internally discovered and developed drug candidates in AstraZeneca's late stage development pipeline.

== Discovery and Development ==
Tralokinumab (CAT-354) was discovered by [[Cambridge Antibody Technology]] scientists<ref name=":0">{{Citation|title = Human Antibody Molecules for Il-13|url = https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2005007699&recNum=238&docAn=GB2004003059&queryString=(FP/antibody)%2520&maxRec=11743|accessdate = 2015-07-26}}</ref> using protein optimization based on [[Ribosome display|Ribosome Display]].<ref>{{Cite journal|title = Tailoring in vitro evolution for protein affinity or stability|url = http://www.pnas.org/content/98/1/75|journal = Proceedings of the National Academy of Sciences|date = 2001-01-02|issn = 0027-8424|pmc = 14547|pmid = 11134506|pages = 75–80|volume = 98|issue = 1|doi = 10.1073/pnas.98.1.75|first = Lutz|last = Jermutus|first2 = Annemarie|last2 = Honegger|first3 = Falk|last3 = Schwesinger|first4 = Jozef|last4 = Hanes|first5 = Andreas|last5 = Plückthun}}</ref> They used the extensive data sets from ribosome display to patent protect CAT-354 in a world-first of sequence-activity-relationship claims.<ref name=":0" /> In 2004, clinical development of CAT-354 was initiated with this first study completing in 2005.<ref name=":1">{{Cite web|title = Tralokinumab - AdisInsight|url = http://adisinsight.springer.com/drugs/800019573|website = adisinsight.springer.com|access-date = 2016-02-20}}</ref> On 21 July 2011, [[MedImmune]] LLC initiated a Ph2b, randomized, double-blind study to evaluate the efficacy of tralokinumab in adults with asthma.<ref>{{ClinicalTrialsGov|NCT01402986|A Phase 2b, Randomized, Double-blind Study to Evaluate the Efficacy of Tralokinumab in Adults With Asthma}}</ref>

As of 2016, MedImmune and AstraZeneca are developing tralokinumab for asthma (Ph3) and atopic dermatitis (Ph2b) while clinical development for moderate-to-severe [[ulcerative colitis]] and idiopathic pulmonary fibrosis (IPF) have been discontinued.<ref name=":1" />

Tralokinumab was licensed to LEO Pharma for skin diseases in July 2016. <ref>https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-enters-licensing-agreements-with-leo-pharma-in-skin-diseases-01072016.html</ref>

== References ==
{{Reflist}}

{{Monoclonals for immune system}}
{{Interleukin receptor modulators}}

[[Category:Monoclonal antibodies]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}